
    
      The treatment period (7 weeks double blind) will aim at demonstrating the efficacy of
      Pitolisant on the number of cataplexy attacks and the Excessive Daytime Sleepiness by
      verifying whether the results of Pitolisant are superior to those of placebo.

      The safety will also be assessed.
    
  